ClinicalTrials.gg
Not yet recruitingNCT07314515ECHOUpdated Feb 24, 2026

The ECHO Study: Compassion-focused Therapy for Young Voice Hearers and Their Caregivers

An interventional study of ECHO Manualized CFT treatment for young voice heares in Hallucinations, Auditory, sponsored by University of Southern Denmark. Not yet recruiting at 1 site in Denmark. Open to participants aged 13 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by University of Southern Denmark · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
13 Years to 21 Years
Sex
All
01

Study summary

In this project, a 10-session treatment program was developed aimed at young people who experience voice hearing. The treatment has potential to easily be implemented in everyday clinical practice in Child and Adolescent Psychiatry, and eventually in Educational Psychological Counselling (PPR) and the newly established STIME services (low-threshold municipal treatment offers for children and young people).

As part of the treatment, the young person's caregivers are involved. This means a high degree of involvement from adults who know the young person well and are part of their daily life.

In addition to traditional Compassion-focuced therapy (CFT), the treatment is expanded with an intervention where an audio file is recorded with content corresponding to the adolescent's voice hearing. The parents are invited to listen to the audio file while participating in a therapy session. This will help improve the caregivers understanding of the young person's experiences and challenges.

02

Conditions studied

  • Hallucinations, Auditory

Browse trials for

Keywords

  • voice hearing
03

In context

Hallucinations

136 studies on the registry are indexed under Hallucinations; 35 are open to participants now.

This study's planned enrollment of 80 is above the median of 48 across 118 interventional studies indexed under Hallucinations.

Browse Hallucinations studies →

Lead sponsor

University of Southern Denmark is the lead sponsor of 336 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participants should have been referred to a child and adolescent psychiatric hospital in Denmark .
  • The participants have heard voices within the last 2 weeks.
  • The participant can hear the content of the voices. The content takes the form of spoken works.
  • A caregiver who can participate in 5 sessions

Exclusion criteria

Exclusion Criteria:

  • Participants has an estimated IQ under 70
  • Participants who don't speak and understand Danish,
  • Current drug misuse / abuse (during sessions)
  • Brain injury or neurological disorder e.g. severe epilepsy
  • Impaired vision or hearing to a degree that makes participation in therapy under normal conditions impossible.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    10 sessions manualized CFT treatment for young voice heares

    60 voice hearing patients age 13-18 years old 20 patients with first-episode schizophrenia age 18-21

    Behavioral: ECHO Manualized CFT treatment for young voice heares

Interventions

  • BehavioralECHO Manualized CFT treatment for young voice heares

    A manualized 10 session, intervention inspired by compassion focused therapy. A primary caretaker paticipates in 5 sessions.

    Also known as: Data is collected 3 months prior to CFT treatment, immediately before the start of treatment, immediately after treatment is completed, and at 1 month follow-up

06

What researchers measure

Primary outcomes

  1. Interpretation and relationship with the voices

    Psychotic symptoms are measured with: BAVQ-R (Beliefs about Voices Questionnaire - Revised) (Chadwick et al., 2000).( 35 items are rated (0-3) total minimum score 0, maximum score 105. Some scores indicate higher distress, while other indicate lower distress).

    Time frame: Data is collected 3 months prior to CFT treatment, immediately before the start of treatment, immediately after treatment is completed, and at 1 month follow-up.

  2. Severity and phenomenological characteristics of voice hearing

    PSYRATS AH (Psychotic Symptoms Rating Scale Auditory Hallucinations) (Haddock et al., 1999). (11 items are rated (0-4) total minimum score 0, maximum score 44. Higher score being more severe)

    Time frame: Data is collected 3 months prior to CFT treatment, immediately before the start of treatment, immediately after treatment is completed, and at 1 month follow-up.

  3. Perceived ability to control or influence the voices

    The Yale Control Over Perceptual Experiences (COPE) Scales measures voluntary control over voices such as being able to intentionally influence the timing, frequency, or intensity of voice hearing experiences (Mourgues et al., 2022). (36 items are rated (1-7) total minimum score 36, maximum score 252. Higher scores indicate stronger perceived control over voices)

    Time frame: Data is collected 3 months prior to CFT treatment, immediately before the start of treatment, immediately after treatment is completed, and at 1 month follow-up.

Secondary outcomes

  1. Social Cognition

    Social cognition is tested with TASIT 2A DK (The Awareness of Social Inference Test) (McDonald et al., 2003). (60 items are rated, minimum total score 0, maximum score is 60. Lower score being more severe)

    Time frame: Social cognition is tested 3 months before treatment and right after

  2. Subjective experience of feeling safe, accepted, and soothed in social relationships.

    SSPS (Social safeness and pleasure scale) (Gilbert et al., 2009). (11 items are rated (1-5). Total minimum 11, total maximum 55. Lower score being more severe).

    Time frame: Data is collected 3 months prior to CFT treatment, immediately before the start of treatment, immediately after treatment is completed, and at 1 month follow-up

  3. Compassion towards self.

    SCS-SF (Self-Compassion Scale Short Form) (Raes et al., 2011; Neff et al., 2019) (12 items are rated (1-5) total minimum 12, total maximum 60. Lower score being more severe).

    Time frame: Data is collected 3 months prior to CFT treatment, immediately before the start of treatment, immediately after treatment is completed, and at 1 month follow-up

  4. Subjective sense of interpersonal closeness and belonging

    The Social Connectedness Scale Revised (Lee et al., 1995; Sabitelli et al., 2005). (8 items are rated (1-6). Total minimum score 8, total maximum score 48. Lower score being more severe).

    Time frame: Data is collected 3 months prior to CFT treatment, immediately before the start of treatment, immediately after treatment is completed, and at 1 month follow-up

  5. Perceived availability and adequacy of social support

    MSPSS (The Multidimensional Scale of Perceived Social Support) (Zimet et al. 1988).(12 items are rated (1-7) total minimum 12, total maximum 84. Lower score being more severe).

    Time frame: Data is collected 3 months prior to CFT treatment, immediately before the start of treatment, immediately after treatment is completed, and at 1 month follow-up

Other outcomes

  1. Primary caregivers

    Factual information about the young person: Education, cohabiting or divorced parents, the young person's residence, family history of mental illness, diagnosis and medication of the young person

    Time frame: Before treatment

  2. Additional questions

    Additionally, questions are asked about how well you feel your parents understand you (e.g., do they know what motivates you and what scares you?) (Likert scale 1-10). Questions about daily stress, sleep, violence and abuse, well-being and quality of life, interaction with family and friends (from the "How are you?" survey among youth in the Central Denmark Region). Quality of life is measured with WHO-5.

    Time frame: Data is collected 3 months prior to CFT treatment, immediately before the start of treatment, immediately after treatment is completed, and at 1 month follow-up

07

Study locations

1 site
  • Psychiatriatric Children and Youth Hospital
    Esbjerg, Denmark
08

References and documents

Publications

  • Heriot-Maitland C. Position paper - CFT for psychosis. Psychol Psychother. 2024 Mar;97(1):59-73. doi: 10.1111/papt.12490. Epub 2023 Aug 14. PubMed 37578215 ↗
  • Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric characteristics of the Multidimensional Scale of Perceived Social Support. J Pers Assess. 1990 Winter;55(3-4):610-7. doi: 10.1080/00223891.1990.9674095. PubMed 2280326 ↗
  • Neff KD, Toth-Kiraly I, Yarnell LM, Arimitsu K, Castilho P, Ghorbani N, Guo HX, Hirsch JK, Hupfeld J, Hutz CS, Kotsou I, Lee WK, Montero-Marin J, Sirois FM, de Souza LK, Svendsen JL, Wilkinson RB, Mantzios M. Examining the factor structure of the Self-Compassion Scale in 20 diverse samples: Support for use of a total score and six subscale scores. Psychol Assess. 2019 Jan;31(1):27-45. doi: 10.1037/pas0000629. Epub 2018 Aug 20. PubMed 30124303 ↗
  • Raes F, Pommier E, Neff KD, Van Gucht D. Construction and factorial validation of a short form of the Self-Compassion Scale. Clin Psychol Psychother. 2011 May-Jun;18(3):250-5. doi: 10.1002/cpp.702. Epub 2010 Jun 8. PubMed 21584907 ↗
  • Gilbert, P., Introducing compassion-focused therapy. Advances in psychiatric treatment, 2009. 15(3): p. 199-208.
  • Mourgues C, Hammer A, Fisher V, Kafadar E, Quagan B, Bien C, Jaeger H, Thomas R, Sibarium E, Negreira AM, Sarisik E, Polisetty V, Nur Eken H, Imtiaz A, Niles H, Sheldon AD, Powers AR. Measuring Voluntary Control Over Hallucinations: The Yale Control Over Perceptual Experiences (COPE) Scales. Schizophr Bull. 2022 May 7;48(3):673-683. doi: 10.1093/schbul/sbab144. PubMed 35089361 ↗
  • Woods, S. W., Parker, S., Kerr, M. J., Walsh, B. C., Wijtenburg, S. A., Prunier, N., Nunez, A. R., Buccilli, K., Mourgues-Codern, C., Brummitt, K., Kinney, K. S., Trankler, C., Szacilo, J., Colton, B.-L., Ali, M., Haidar, A., Billah, T., Huynh, K., Ahmed, U., Adery, L. L., Marcy, P. J., Allott, K., Amminger, P., Arango, C., Broome, M. R., Cadenhead, K. S., Chen, E. Y. H., Choi, J., Conus, P., Cornblatt, B. A., Glenthøj, L. B., Horton, L. E., Kambeitz, J., Kapur, T., Keshavan, M. S., Koutsouleris, N., Langbein, K., Lavoie, S., Diaz-Caneja, C. M., Mathalon, D. H., Mittal, V. A., Nordentoft, M., Pasternak, O., Pearlson, G. D., Gaspar, P. A., Shah, J. L., Smesny, S., Stone, W. S., Strauss, G. P., Wang, J., Corcoran, C. M., Perkins, D. O., Schiffman, J., Perez, J., Mamah, D., Ellman, L. M., Powers, A. R. III, Coleman, M. J., Anticevic, A., Fusar-Poli, P., Kane, J. M., Kahn, R. S., McGorry, P. D., Bearden, C . E., Shenton, M. E., Nelson, B., Calkins, M. E., Hendricks, L., Bouix, S., Addington, J., McGlashan, T. H., Yung, A. R., & The Accelerating Medicines Partnership Schizophrenia (2024). Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS. Early Intervention in Psychiatry, 18(4), 255-272. https://doi.org/10.1111/eip.13457
  • Chandwick P, Lees S, Birchwood M. The revised Beliefs About Voices Questionnaire (BAVQ-R). Br J Psychiatry. 2000 Sep;177:229-32. doi: 10.1192/bjp.177.3.229. PubMed 11040883 ↗
  • McDonald S, Flanagan S, Rollins J, Kinch J. TASIT: A new clinical tool for assessing social perception after traumatic brain injury. J Head Trauma Rehabil. 2003 May-Jun;18(3):219-38. doi: 10.1097/00001199-200305000-00001. PubMed 12802165 ↗
  • Musaeus MK, Heriot-Maitland C, Bliksted VF. The ECHO study: compassion-focused therapy for young voice hearers and their caregivers. A pilot study. Front Psychiatry. 2026 Jul 10;17:1827986. doi: 10.3389/fpsyt.2026.1827986. eCollection 2026. PubMed 42500314 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

Of 53 non-industry interventional studies with no phase under Hallucinations, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 24 months is below that.

Counting every sponsor, half of 53 studies reached it within 37 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Jan 2, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jan 2029
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07314515
Collaborators
Region Syddanmark
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Feb 24, 2026

Study contacts

Maja K Musaeus, Psychologist
Contact
maja@musaeus.eu
+4591543221
Vibeke F Bliksted, Professor
Contact
vibeke.fuglsang.bliksted@rsyd.dk
Charlie Heriot-Maitland, Dr.
study chair · Balanced Minds

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion